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Micelles have become one of the main players in nanoparticle
research. Although micelles have been around for decades, it was not
until recently that these particles were finally utilized in advanced
drug delivery systems. Micelles formation is an efficient method for
delivering poorly water-soluble drugs [1], and its usefulness is in
particular applicable to chemotherapeutic agents [2]. Polymer-based
micelles have been the main focus of researchers in the past several
years. Cancer has unique characteristics that can be exploited for drug
delivery. Tumor vasculature specifically has become a burgeoning area
of research over the past few decades. The enhanced permeability and
retention effect (EPR) in solid tumors is one of the main reasons that
polymeric micelles are able to selectively distribute to tumor cells as
opposed to normal tissues [3]. Bradykinin, nitric oxide, peroxynitrite,
and VEGF are vascular permeability factors found to be elevated in the
tumor environment which enhances angiogenesis [4]. Collagenases
also help induce vascular permeability by causing disintegration of
matrix tissue surrounding blood vessels [4]. Fenestrations in regular
vessels are too small for penetration of nanoparticles, compared to
those as large as 600-800 nm in tumor tissue [3]. Therefore, polymeric
micelles are able to penetrate tumor tissue selectively, achieve
higher concentrations, and have a longer duration of action than
regular dosage forms, subsequently requiring less dosing. Regular
body processes also play a role in drug permeability and retention.
The reticuloendothelial system (RES), comprised of monocytes and
macrophages, is responsible “for engulfing and clearing old cells,
miscellaneous cellular debris, foreign substances, and pathogens
from the bloodstream” [5]. Polymeric micelles are able to effectively
avoid opsonization by the RES and achieve longer circulation times.
Longer circulation times again allow enhanced permeability to tissues
resulting in a greater therapeutic response.
Understanding micelle structure is a key to realizing their potential
as novel drug delivery systems. Micelles are surfactant molecules,
which aggregate in aqueous or oily liquids [4]; the micelles occupy
the dispersed phase of a colloidal system [6]. Amphipathic monomers,
each containing a hydrophilic and hydrophobic domain, make up a
polymeric micelle. Micelle’s ability to aggregate and carry drugs is
conferred by a property known as the critical micelle concentration
(CMC). These amphipathic monomers do not aggregate until the
CMC is reached, at which time spontaneous aggregation occurs
resulting in polymeric micelles. CMC values for nanoparticles are
generally much lower than most commercially available products (on
the order of 10 -6 or 10 -7); if the micelles faced dilution, (i.e., injection
into the body) then a drop in concentration below the CMC would
cause loss of structural integrity. The CMC phenomenon is due
to the dehydration of the hydrophobic tails, leading to a favorable
state of entropy [4]. The hydrophobic domains comprise the micelle
“core” while the hydrophilic domains make up the micelle exterior
or “corona” [3]. Hydrophobic cores are ideal for encapsulating
hydrophobic drugs, which is where most research has been focused
and has found success. Formation of van der Waals bonds between
the hydrophobic polymer core and drug help stabilize the micelle.
The hydrophilic corona also helps stabilize the micelle structure due
to the formation of hydrogen bonds with the surrounding aqueous
solution [4]. Encapsulation of hydrophilic drugs has been attempted,
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but currently has been unsuccessful and needs to be studied further.
The entire complex of micelle and drug can then vary in size from
ten to hundreds of nanometers; although, nanoparticles under 100
nm seem to fair the best in vivo. So how would someone realistically
create these compounds? There are several popular methods of
nanoparticle synthesis which will be highlighted: emulsificationsolvent evaporation, solvent displacement, and salting out.
Emulsification-solvent evaporation usually utilizes a simple
emulsion (w/o) or double emulsion (w/o/w) technique. Simple
emulsions are used mainly for hydrophobic drugs. Like most
stabile emulsions, sufficient shear is needed to disperse the aqueous
phase in the organic solvent. Dichloromethane, ethyl alcohol, and
other volatile solvents immiscible with water are used commonly
as organic solvents, while drugs mixed with the chosen polymer
occupy the dispersed phase. The dispersed phase must also contain
appropriate levels of surfactant (sodium cholate, poly-vinyl alcohol,
etc) to form micelles with the drug molecules. In order to provide
the necessary amount of shear, complex methods of mixing, such
as homogenization or probe sonication are employed. Micelles are
collected by centrifugation after mixing, the solvent is removed by
evaporation, and the final product is distributed in water. A double
emulsion is formed similarly; however, when the primary emulsion
(w/o) is formed with the drug and organic solvent, this emulsion is
then dispersed throughout another aqueous phase (w/o/w). Double
emulsions are useful for encapsulating hydrophilic drugs [7].
Solvent Displacement, also known as nanoprecipitation or solvent
diffusion, was first described by Fessi et al. (1989) [8]. In this method,
solvents miscible with water are used (acetone, etc). The drug, polymer,
and surfactants are dispersed throughout the organic phase. “A
submicron o/w emulsion is spontaneously formed due to immediate
reduction of the interfacial tension with rapid diffusion of acetone
into the aqueous phase (the Marangoni effect)” [7]. The final steps are
similar to the emulsification-solvent evaporation method; however,
solvent displacement is not used to encapsulate water-soluble drugs.
Advantageously, lesser shear is required in this method [7].
The salting out method can be used to encapsulate hydrophobic
drugs only. A primary o/w emulsion is formed with the drug and
polymer in the organic phase. “As salting out agents can be used
electrolytes, such as magnesium chloride, sodium chloride, or
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magnesium acetate and non-electrolytes, such as sucrose” [7]. The
main purpose of the salting out agent is to make a usually watersoluble solvent such as acetone insoluble by supersaturating the
solution. Acetone diffusion into the aqueous phase then causes the
formation of nanoparticles [9].
Synthesis of the polymeric micelle is a tricky task itself. However,
once formed, micelles must achieve the proper therapeutic effect, last
for a desired amount of time, and be eliminated with ease without any
complications. As knowledge of micelle structure and kinetics grows,
drug delivery utilizing polymeric micelles will become smarter. The
basis of any drug’s structure is its inherent components and size.
Polymer-based micelles, specifically A-B co-block polymers, have
gained much attention recently. In this structure the A segment is
hydrophilic and the B segment is hydrophobic. Polyethylene glycol
is the most commonly used hydrophilic segment because it is a FDA
approved nontoxic polymer [3]. Poly(lactide-co-glycolide)(PLGA) is
the most commonly used hydrophobic segment in research. However,
many other compounds or variations can and have been used. An
increase in the internal/external phase ratio leads to a slight decrease
of the nanoparticle’s average size, whereas a nanoparticle size increase
was observed when the polymer/surfactant ratio was higher [9].
The preparation of nanoparticles via emulsion based techniques
requires the use of compounds to stabilize the formulation. Poly(vinyl
alcohol)(PVA) and human serum albumin (HSA) have been used
effectively as stabilizers in Doxorubicin-loaded PLGA nanoparticles.
PVA seems to be more effective; however, Lecithin has been used to
increase the activity of HAS and found to be better than PVA [10].
Nanoparticle size appears to decrease with increases in stabilizer
concentration between 0.5 and 5% w/v [9]. In order to make sure
adequate levels of drug are being delivered inside nanoparticles,
one must study several parameters: Nanoparticle recovery (%) and
encapsulation efficiency, which is broken down into drug content
(drug loading, % w/w) and drug entrapment (%). Changing the
aqueous phase pH from 5.8 to 9.3 increased procaine hydrochloride
nanoparticle recovery from 65.1 to 93.4%, drug content from
0.3 to 1.3% (w/w), and drug entrapment from 11.0 to 58.2% [11].
Poly(styrene-co-maleic acid)(SMA)-tanespimycin micelles were
reported with a loading efficiency of 93%, while an even higher
loading efficiency with Paclitaxel nanoparticles of 96% was seen
[12,13]. The loading efficiency of Paclitaxel nanoparticles was found
to be decreased when the external aqueous phase volume was doubled
(nanoprecipitation method). The method of preparation of the
organic phase may also influence the loading efficiency [14]. Some
strives have been made to simulate the compatibility of drugs with
certain co-block polymers. In one example with PEO-b-PCL block
copolymers, Flory-Huggins interaction parameters were found to be
more consistent with experimental solubility data than the traditional
group contribution method used in the pharmaceutical industry
[15]. Regardless of the design, it is important to note that high
nanoparticle recovery is required for reducing manufacturing costs.
High entrapment efficiency will reduce the amount of carrier needed
for the administration to the target site and help eliminate wastage
during manufacturing.
Other studies have examined the possibility of multiple drug
carriers. It is well known that chemotherapy regimens using multiple
drugs will enhance tumor inhibition. For example, common
acronyms such as TAC, CMF, or TCH denote combination therapies
for breast cancer [16]. Beyond inhibiting tumor growth, combination
nanoparticle drugs will allow better dosage optimization and
convenience. Unimers of Doxorubicin and Camptothecin conjugated
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to poly-L-lactide (PLA) can be controlled ratiometrically with over
90% loading efficiency. This control is achieved simply by adjusting
the DOX-PLA:CPT-PLA molar ratio. This dual drug combination was
proven to exhibit more cellular cytotoxicity than single drug-loaded
nanoparticles [17]. Nanoparticles co-loaded with Doxorubicin and
Paclitaxel in a concentration ratio of 2:1 showed high anti-tumor
activity against three different types of tumor cells [18]. Again, these
co-loaded nanoparticles were found to be superior to single drug
formulations. A 3-in-1 injection of Poly(ethylene glycol)-blockpoly(D,L-lactic acid)(PEG-b-PLA) micelles carrying the three anticancer drugs Paclitaxel, 17-allyamino-17demethoxygeldanamycin,
and rapamycin reduced tumor volume by 1.6 fold [19].
Once ready to be administered, micelles are injected and enter
cells by endocytosis. Drug targeting to specific cells can be specialized
through ligand-receptor interactions. Octreotide conjugated micelles
carrying Docetaxel were found to be a viable option for delivery to
tumor cells over expressing the somatostatin receptor. This receptor
is found over-expressed in many types of tumors such as prostate and
breast cancer and regulates inhibition of hormone and growth factor
secretion [20]. A ligand for Melanocortin 1 receptor, a ligand overexpressed in melanomas, was found to bind effectively and selectively
while conjugated to micelles. However, some loss of affinity was noted
when small peptides were attached to larger micelles [21]. Integrinανβ3 receptor, over-expressed in angiogenic tumor blood vessels, can
be targeted using Arg-Gly-Asp (RGD); Folic acid can also be used to
target the folate receptor over-expressed in many breast, lung, kidney,
and brain cancers. An increase in uptake of RGD and folic acid
conjugated nanoparticles to HUVEC and KB cells respectively was
seen. Uptake was modulated by increasing or decreasing the density
of the ligands on the nanoparticle surface [22]. Micelles modified
with anti-nucleosome monoclonal antibody 2C5 demonstrated
higher cytotoxicity in tumor cells than free drug against the B16
(murine melanoma) and 4T1 (murine mammary carcinoma) cell
lines [23]. AS1411 is a DNA aptamer that specifically binds nucleolin,
which is highly expressed in cancer cells and endothelial cells lining
angiogenic blood vessels. Nanoparticles conjugated with AS1411 and
carrying Paclitaxel enhanced uptake and thus tumor inhibition in C6
glioma cells. Entry of micelles into the cell has been explored by these
methods and others as well; however, once inside, triggers exist to
potentially obtain even better drug targeting.
Multiple methods of activation have been studied for nanoparticle
release including: pH, temperature, ultrasound, light, and chemical
reactions. One interesting example utilizes polymers conjugated
to histidine and phenylalanine. These poly(L-histidine-co-Lphenylalanine) polymers are blended with poly(L-lactic acid)-b-PEGfolate (PLLA-b-PEG-folate) polymers in order to create a micelle that
targets early endosomal pH (roughly pH 6). The histidine moiety, with
a pKa of around 6.5, transitions from hydrophobic properties at high
pH, (>7.0) to hydrophilic properties at low pH (<7.0) due to ionization
of the imidazole group at lower pH. However, the histidine conjugated
polymers must be conjugated with phenylalanine moieties and then
blended with PLLA-b-PEG-folate polymers in order to: i) create a drug
effective against multi-drug resistant (MDR) tumors and ii) allow
the micelle structure to maintain shape at physiological pH (pH 7.4)
and still release drug at the tumor site when engulfed by endosomes
(pH 6) [24]. Micelles synthesized with poly(N-isopropylacrylamide)
(PNIPAAm) have a thermosensitive property that allows them
to maintain stability at 37° Celsius and deform at 39.5° Celsius to
release Doxorubicin [25]. Doxorubicin loaded micelles also were
shown to enter cells and be released effectively by ultrasound. Yield
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of intraperitoneal ovarian carcinoma tumors decreased from 70% for
Doxorubicin to 36% for the same concentration of Doxorubicin loaded
micelles with a 30 second sonication. This effect was independent of
temperature, because of its occurrence at low ultrasound energies,
well below that used for hyperthermia tumor treatment. The effect is
thought to be related to ultrasound’s ability to cause cell membrane
disruption, resulting in a transient increase in cell membrane
permeability of the tumor interstitial environment [26]. Micelle
polymers conjugated with photochromic spiropyran (SP) units
undergo reversible isomerization between colorless SP and colored
merocyanine (ME). Irradiation with UV light (365 nm) completely
disrupted the micelles, while irradiation with visible light (620 nm)
effectively reversed the dissociation. This delivery system was used to
carry the hydrophobic dye coumarin 102 [27]. Novel mechanisms will
enable increased drug specificity for tumor tissue.
Once micelles are triggered, then how would we characterize their
release profile? It has been well-documented that most polymeric
micelles exhibit a biphasic release profile. Micelles containing
procaine hydrochloride exhibited immediate release of about 65%
over 15 minutes followed by release of the remaining drug over
4-6 hours [11]. Micelles containing Paclitaxel were found to release
roughly 30% of the drug after 12 hours, followed by sustained release
of roughly 65% of the drug over 72 hours [14]. Tanespimycin release
from micelles occurred at 51% and 95% over 2 and 8 hours, respectively
[12]. Sustained release was noted with release of Tamoxifen citrate
from micelles conjugated with guar gum. Here it was noted that the
predominant mechanism behind drug release was time dependent
release and diffusion [28]. However, this is consistent with theories
given by other researchers reporting biphasic release profiles, since it
is believed that the initial rapid release is caused by drug adsorbed or
close to the surface of the nanoparticles and large surface to volume
ratio, while the sustained release may be due to diffusion of the drug
from the core [11]. Biphasic release would be desirable since a drug’s
effect would then be immediate and long-lasting. Overall, it appears
that the biphasic release characteristics of micelle systems vary with
its composition. This would lead one to believe that desirable release
characteristics could be achieved simply by changing these molecules.
Contributions in this field could lead to a need for less dosing or
reduced toxicity.
So what are some practical, in vivo applications of micelle systems?
There are several FDA approved compounds that are currently in use
for certain types of cancer. However, given the amount of research on
micelles, FDA approved compounds remain relatively few: GenexolPM, Oncaspar, and Abraxane. Published data associated with micelle
toxicity is slim, probably due to the fact that there is a penchant to
publish positive results. In addition, due to the increased specificity
for target tissues, nanoparticles are less likely to cause systemic side
effects. Toxic substances used in conventional drug delivery may
become unnecessary if micelles dosage form is used instead. For
example, an excipient in the formulation of Paclitaxel, Cremophor
EL, has been associated with severe hypersensitivity reactions.
Preparation of nanoparticles without Cremophor EL has been shown
to reduce these undesirable reactions.
Micelles appear to have some role in delivering chemotherapeutic
agents in an efficient and targeted way. However, complexity of
preparation and stability remain issues of concern regarding this
dosage form.
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